Gamida Cell (NASDAQ: GMDA) is one of 255 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Gamida Cell to similar businesses based on the strength of its dividends, valuation, risk, profitability, earnings, analyst recommendations and institutional ownership.
Earnings & Valuation
This table compares Gamida Cell and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Gamida Cell||N/A||-$52.93 million||-1.09|
|Gamida Cell Competitors||$47.41 million||-$65.11 million||-21.74|
Insider & Institutional Ownership
1.7% of Gamida Cell shares are owned by institutional investors. Comparatively, 51.7% of shares of all “Biotechnology” companies are owned by institutional investors. 21.5% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares Gamida Cell and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Gamida Cell Competitors||-4,789.27%||-257.83%||-37.30%|
This is a breakdown of recent ratings and price targets for Gamida Cell and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Gamida Cell Competitors||372||1484||3800||83||2.63|
Gamida Cell currently has a consensus target price of $19.40, suggesting a potential upside of 68.70%. As a group, “Biotechnology” companies have a potential upside of 2.98%. Given Gamida Cell’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Gamida Cell is more favorable than its rivals.
Gamida Cell beats its rivals on 8 of the 12 factors compared.
About Gamida Cell
Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases in the United States, the European Union, and internationally. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in a patients with high-risk blood cancers, as well as in Phase I/II studies in patients with severe aplastic anemia. It is also developing NAM-NK, an innate immunotherapy, which is in Phase I studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.